Acute Myocardial Infarction Clinical Trial
Official title:
IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis
Background: Percutaneous coronary intervention (PCI) is a highly effective therapy for acute
ST-elevation myocardial infarction (STEMI). Adjunctive therapy with glycoprotein (GP)
IIb/IIIa inhibitor can result in increased patency and improved outcomes in STEMI patients,
with thrombus, undergoing PCI. The investigation of novel dosing and delivery strategies of
this therapy may help to further improve outcomes.
Study design: Intracoronary Abciximab With Clearway Catheter trial is a randomized,
open-label, multicenter, trial to evaluate the effect of an intracoronary (IC) bolus dose of
abciximab delivered using the ClearWay™RX catheter versus an intravenous bolus (IV) of
abciximab for STEMI with angiographically visible thrombus (Thrombus Grade > 2). All
patients in both arms will receive intravenous abciximab infusion following the PCI for 12
hours per standard practice. A total of 150 patients will be randomized 1:1 to treatment of
the culprit artery with IC abciximab (75 subjects) or IV abciximab (75 subjects) in addition
to an infusion regimen of abciximab administered intravenously and initiated following PCI.
The primary endpoint chosen to evaluate this hypothesis is infarct size as assessed on
Cardiac Magnetic Resonance (CMR). Clinical outcomes will be assessed for each subject
through hospital discharge and at 30 day follow-up.
Sample size: The number of patients included in this study was based on the estimation of
the sample size needed to identify a statistically significant difference of the primary
end-points between the two groups. The investigators estimated that 75 patients would be
required in each study group to have a power of 80% to detect an absolute difference in the
infarct size resolution of 15% with a two-sided alpha value of 0.05.
Conclusion: The purpose of this study is to demonstrate that an IC bolus of abciximab
delivered with the ClearWay™RX catheter added to a post-PCI intravenous infusion regimen of
abciximab will result in significant additional clot resolution in vivo when compared with
an IV bolus of abciximab when added to a post PCI intravenous infusion regimen of abciximab.
The primary endpoint chosen to evaluate this hypothesis is infarct size as assessed on CMR.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04451967 -
Acute Myocardial Infarction Study in Northeastern China
|
||
| Completed |
NCT05974397 -
Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
|
||
| Not yet recruiting |
NCT04072081 -
Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions
|
N/A | |
| Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
| Recruiting |
NCT03707626 -
Collateral Circulation to LAD and Wellens Sign
|
||
| Completed |
NCT02669810 -
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
|
Phase 2 | |
| Not yet recruiting |
NCT04104048 -
Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
|
||
| Active, not recruiting |
NCT02915107 -
The SORT OUT IX STEMI OCT Trial
|
N/A | |
| Completed |
NCT02896543 -
The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction
|
N/A | |
| Completed |
NCT02531165 -
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT02490969 -
Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
|
N/A | |
| Withdrawn |
NCT01901471 -
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
|
Phase 2 | |
| Completed |
NCT02312336 -
A Pilot Study of Transcoronary Myocardial Cooling
|
N/A | |
| Recruiting |
NCT02071342 -
Study of ABSORB Stent in Acute Myocardial Infarction
|
N/A | |
| Terminated |
NCT01972126 -
MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction
|
N/A | |
| Completed |
NCT02070913 -
COOL-AMI EU Case Series Clinical Study
|
||
| Completed |
NCT01216995 -
Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)
|
Phase 2 | |
| Withdrawn |
NCT01678339 -
Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
|
N/A | |
| Completed |
NCT01887080 -
Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program
|
N/A | |
| Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A |